The Healthtech Podcast #377 The Role of Psychedelics in Modern Psychiatry with Cosmo Feilding Mellen
Nov 27, 2024
Cosmo Feilding Mellen, co-founder and CEO of Beckley Psytech, is a pioneer in psychedelic medicine aimed at treating neuropsychiatric disorders. He discusses the revival of psychedelic research and its historical context, the fascinating intersection of anesthetics and psychedelics in psychiatry, and the innovative next-gen compounds being developed. Mellen also explores the cultural shift towards destigmatizing mental health, envisioning psychedelics as integral to future psychiatric care. Join the discussion on the exciting evolution of mental health treatment!
AI Snips
Chapters
Transcript
Episode notes
Family History
- Cosmo Feilding Mellen's mother, Amanda Feilding, co-founded Beckley Psytech.
- She has been involved in psychedelic research for 50 years and founded the Beckley Foundation.
Resurgence of Psychedelic Research
- The resurgence of psychedelic research is due to multiple converging factors.
- These include new technologies, growing mental health awareness, and a lack of innovation in psychiatry.
Psychedelics and the Default Mode Network
- Brain imaging studies revealed psychedelics downregulate the default mode network, overly active in addiction and depression.
- This downregulation and increased brain connectivity suggests a mechanism for treating these conditions.